| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | NextPoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $196.84M | Series B | 7/30/2026 | $156.21M | $356.79M | $6.00 | Catalio Capital, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Binney Street Capital, Gordon Freeman, Arkin Capital, WTT Investment, PagodaTree Partners | ||||
 | Pathalys Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $146.75M | Series B | 8/20/2024 | $105M | $284.99M | $10.85 | TCG Crossover Management, JP Morgan, Samsara BioCapital, Marshall Wace, KB Investment, Japan Post Investment, Catalys Pacific, DaVita Venture Group | ||||
 | Pyxis Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $194.5M | Series B | 3/30/2021 | $172.5M | $273.43M | $10.47 | Arix Bioscience, RTW Investments, Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, Tekla Capital Management, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital, Laurion Capital Management, Logos Capital, LifeSci Venture Partners, Leaps by Bayer, Agent Capital, Ipsen Ventures, Longwood Fund, 3E Bioventures | ||||
 | SPR Therapeutics | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $104.49M | Series D-1 | 2/1/2024 | $25.64M | $263.67M | $27.44 | Revelation Partners, RC Capital, Mutual Capital Partners | ||||
 | Tizona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $95.24M | Series B-3 | 1/3/2019 | $15M | $173.78M | $1.60 | AbbVie | ||||
 | Avail | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $132.86M | Series B | 10/7/2020 | $100M | $300.42M | $1.18 | D1 Capital Partners, 8VC | ||||
 | Cagent Vascular | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $110.64M | Series D | 5/19/2026 | $41M | $166.6M | $0.28 | Astoria Health Investors, U.S. Venture Partners, BF Belmont, Trinity Capital | ||||
 | Dren Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $128.57M | Series B | 3/16/2022 | $62.5M | $285.71M | $3.40 | HBM Healthcare Investments | ||||
 | Firefly Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $146.01M | Series C | 10/25/2024 | $60M | $348.01M | $6.26 | Undisclosed Investors | ||||
 | HI-Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $22.2M | Series A | 10/20/2022 | $20M | $97.78M | $0.71 | Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute | ||||
 | Korro Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $593.6M | Series B-2 | 1/5/2022 | $45.12M | $290.4M | $2.78 | Eventide Asset Management, Fidelity, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital, Atlas Venture, NEA, Wu Capital, Qiming Venture Partners, Surveyor Capital, Cormorant Asset Management, MP Healthcare Venture Management, Alexandria Venture Investments | ||||
 | Mariana Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $250M | Series B | 9/7/2023 | $175M | $311.65M | $1.06 | Deep Track Capital, Forbion, Atlas Ventures, Access Biotechnology, RA Capital Management, Nextech Invest, Surveyor Capital, Eli Lilly and Company | ||||
 | Octagos Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $53.16M | Series B | 7/9/2024 | $28.73M | $107.58M | $31.13 | Morgan Stanley, Mucker Capital | ||||
 | PatientPop | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $125.82M | Series C | 8/25/2020 | $42.65M | $425.93M | $9.93 | HLM Venture Partners, Commonfund, Vivo Capital, Toba Capital, Transformation Capital, Silicon Valley Bank | ||||
 | Stimwave | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $89.02M | Series E | 8/28/2020 | $3.27M | $235.28M | $16.50 | Undisclosed Investors | ||||
 | Tend | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $475.01M | Series D | 7/30/2024 | $72.23M | $276.08M | $0.77 | Undisclosed Investors | ||||
 | Twill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $90.83M | Series D | 3/17/2021 | $31M | $409.29M | $8.14 | Deerfield Management Company, Omega Capital Partners, ION Crossover Partners | ||||
 | Cargo Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $507.54M | Series A-1 | 7/31/2023 | $86.04M | $302.29M | $13.57 | Ally Bridge Group, Cormorant, NexTech, Piper Heartland, Piper Sandler, RTW Sandler, RTW Investments, Third Rock Ventures, T. Rowe Price, Wellington, Xontongey, Janus Henderson, Emerson Collective, Red Tree Venture, Samsara BioCapital, Cormorant Capital | ||||
 | Delphinus Medical Technologies | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $628.96M | Series E | 6/20/2023 | $5M | $208.48M | $0.69 | Trinity Capital Inc. | ||||
 | Disc Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $145M | Series B | 9/2/2021 | $90M | $253.72M | $2.40 | OrbiMed, Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, Alexandria Venture Investments, Novo Holdings A/S, Access Biotechnology, Atlas Venture | ||||
 | EndoGastric Solutions | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $377.99M | Series J | 11/25/2020 | $27M | $448.42M | $2.51 | Vertex Growth Fund | ||||
 | Endovascular Engineering | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $141.7M | Series C-2 | 4/7/2026 | $30M | $213.1M | $0.92 | Gilde Healthcare, Norwest, Sante Ventures, 415 Capital, S3 Ventures, Panakes Partners, M&L Healthcare | ||||
 | Goldfinch Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $190.22M | Series B | 6/30/2020 | $105.91M | $252.06M | $1.18 | Eventide Asset Management, Wellington Management Company, Ally Bridge Group, BlackRock, Casdin Capital, Irving Investors, Gilead Sciences, Yonjin Capital, Schroeder Adveq | ||||
 | Jnana Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $414.4M | Series C-2 | 11/15/2022 | $47M | $292.93M | $0.89 | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | ||||